Posted by Michael Wonder on 06 May 2024
Taysha Gene Therapies announces regenerative medicine advanced therapy designation granted by US FDA for TSHA-102 in Rett syndrome
2 May 2024 - RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and paediatric).
Taysha Gene Therapies today announced the US FDA has granted regenerative medicine advanced therapy designation to TSHA-102, a self complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
